文献速递肿瘤 PET/CT放射性药物与辐射防护

99mTc-(HE)3-G3(DARPin类HER2显像探针)乳腺癌I期试验

Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer.
PubMed 文献 · J Nucl Med · 2021-08-12

该首次人体I期研究在原发性乳腺癌患者中评估99mTc-(HE)3-G3的安全性、生物分布与剂量学,患者分3组分别注射1,000、2,000或3,000 μg(287 ± 170 MBq)。结果显示注射耐受良好、无副作用,血液清除快,肾和肝摄取最高,有效剂量平均0.011 ± 0.004 mSv/MBq,HER2阳性肿瘤在注射后2和4小时的肿瘤/对侧比值显著高于HER2阴性。

要点

  • 99mTc-(HE)3-G3注射耐受良好,未观察到副作用。
  • 有效剂量平均0.011 ± 0.004 mSv/MBq。
  • HER2阳性肿瘤2和4小时肿瘤/对侧比值显著高于阴性。

核心结论

  • 使用99mTc-(HE)3-G3进行HER2表达显像安全、耐受良好,对患者造成的吸收剂量负担低。
  • 该显像能够区分HER2阳性与HER2阴性乳腺癌。
  • I期研究数据支持99mTc-(HE)3-G3的进一步临床开发。

研究设计与样本

  • 首次人体I期研究,纳入原发性乳腺癌患者,分3组分别注射1,000、2,000或3,000 μg的99mTc-(HE)3-G3(287 ± 170 MBq)。
  • 每组至少包括4例HER2阴性肿瘤和5例HER2阳性肿瘤患者。
  • 注射后2、4、6和24小时进行全身平面显像及SPECT,并监测生命体征及可能副作用至注射后7天。

主要发现

  • 所有注射均耐受良好,未观察到副作用,研究前后血液和尿液分析结果无差异。
  • 99mTc-(HE)3-G3从血液中快速清除。
  • 摄取最高的器官为肾脏和肝脏,其后为肺、乳腺和小肠内容物。
  • 注射2,000或3,000 μg后的肝脏摄取显著(P < 0.05)低于注射1,000 μg后的摄取。
  • HER2阳性肿瘤在注射后2和4小时的肿瘤/对侧比值显著(P < 0.05)高于HER2阴性肿瘤。

关键数值与推荐

  • 各队列间有效剂量无显著差异,平均为0.011 ± 0.004 mSv/MBq。
  • 注射2,000或3,000 μg后的肝脏摄取显著(P < 0.05)低于注射1,000 μg后的摄取。
  • HER2阳性肿瘤在注射后2和4小时的肿瘤/对侧比值显著(P < 0.05)高于HER2阴性肿瘤。

临床怎么用

  • 该探针可用于无创区分HER2阳性与HER2阴性乳腺癌,为HER2靶向治疗的患者分层提供依据。
  • 显像安全性良好且吸收剂量负担低,支持进一步临床开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radionuclide molecular imaging of human epidermal growth factor receptor type 2 (HER2) expression may enable a noninvasive discrimination between HER2-positive and HER2-negative breast cancers for stratification of patients for HER2-targeted treatments. DARPin (designed ankyrin repeat proteins) G3 is a small (molecular weight, 14 kDa) scaffold protein with picomolar affinity to HER2. The aim of this first-in-humans study was to evaluate the safety, biodistribution, and dosimetry of 99mTc-(HE)3-G3. Methods: Three cohorts of patients with primary breast cancer (each including at least 4 patients with HER2-negative and 5 patients with HER2-positive tumors) were injected with 1,000, 2,000, or 3,000 μg of 99mTc-(HE)3-G3 (287 ± 170 MBq). Whole-body planar imaging followed by SPECT was performed at 2, 4, 6, and 24 h after injection. Vital signs and possible side effects were monitored during imaging and up to 7 d after injection. Results: All injections were well tolerated. No side effects were observed. The results of blood and urine analyses did not differ before and after studies. 99mTc-(HE)3-G3 cleared rapidly from the blood. The highest uptake was detected in the kidneys and liver followed by the lungs, breasts, and small intestinal content. The hepatic uptake after injection of 2,000 or 3,000 μg was significantly (P < 0.05) lower than the uptake after injection of 1,000 μg. Effective doses did not differ significantly between cohorts (average, 0.011 ± 0.004 mSv/MBq). Tumor-to-contralateral site ratios for HER-positive tumors were significantly (P < 0.05) higher than for HER2-negative at 2 and 4 h after injection. Conclusion: Imaging of HER2 expression using 99mTc-(HE)3-G3 is safe and well tolerated and provides a low absorbed dose burden on patients. This imaging enables discernment of HER2-positive and HER2-negative breast cancer. Phase I study data justify further clinical development of 99mTc-(HE)3-G3.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bragina O, Chernov V, Schulga A, et al. Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer. J Nucl Med. 2021. PMID: 34385343. doi:10.2967/jnumed.121.262542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。